Michael J. Mitten

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

Tumor Biology, Bcl-2 Family Proteins, Medicine +9

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 1.9K citations · Full text

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert et al. · Science Translational Medicine · 2015 · 530 citations · Full text

Cancer Therapy, Chemoprevention Strategy, Bcl-2/bcl-xl/bcl-w Inhibitor Abt-263 +20

Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 328 citations · Full text